Medical Training AIDMARDs and Biologics
You'll be able to select, sequence, and monitor conventional DMARDs, biologics, and JAK inhibitors based on mechanism, safety profile, and treatment goals.
What this track covers
This track covers the pharmacology and clinical use of conventional DMARDs, TNF inhibitors, non-TNF biologics, and JAK inhibitors in rheumatic disease management. It emphasizes drug selection, safety monitoring, and strategies for switching or combining agents, including biosimilar considerations.
What you will practice
- Differentiate mechanisms of action across DMARD classes and biologic targets
- Choose an initial agent based on disease activity, comorbidities, and contraindications
- Build a baseline and ongoing lab monitoring schedule for a given agent
- Screen for infection risk and vaccination needs before starting biologic therapy
- Decide when to switch, combine, or transition to a biosimilar after inadequate response
Simulator scenario
A patient with inadequate response to methotrexate monotherapy presents to discuss next steps, requiring the clinician to weigh combination therapy versus adding a biologic.
Board question topics
- Mechanism of action of conventional DMARDs
- Pre-biologic screening and monitoring requirements
- Distinguishing features of JAK inhibitors
- Treat-to-target and switching strategies
Ask the tutor
The tutor only answers from licensed sources (FDA prescribing information, public guidelines and our own material) and says when it has none. Educational use only, never patient-specific advice.
Free during the beta. Sign in with your email, no password.
Start free